Andy van Hateren
Overview
Explore the profile of Andy van Hateren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Hateren A, Elliott T
Curr Opin Immunol
. 2023 May;
83:102340.
PMID: 37245412
Which peptides are selected for presentation by major histocompatibility complex class-I (MHC-I) molecules is a key determinant of successful immune responses. Peptide selection is co-ordinated by the tapasin and TAP...
2.
Brown L, Wagg J, Darley R, van Hateren A, Elliott T, Gaffney E, et al.
Immunother Adv
. 2022 Sep;
2(1):ltac017.
PMID: 36176591
Drug development typically comprises a combination of pre-clinical experimentation, clinical trials, and statistical data-driven analyses. Therapeutic failure in late-stage clinical development costs the pharmaceutical industry billions of USD per year....
3.
van Hateren A, Elliott T
Curr Opin Immunol
. 2021 Jul;
70:138-143.
PMID: 34265495
Major Histocompatibility Complex class I (MHC I) molecules are highly polymorphic, with allotypes differing in peptide binding preferences, and in their dependence upon tapasin for optimal peptide selection. The tapasin...
4.
Illing P, van Hateren A, Darley R, Croft N, Mifsud N, King S, et al.
Front Immunol
. 2021 Jun;
12:672737.
PMID: 34093574
Abacavir hypersensitivity syndrome can occur in individuals expressing the HLA-B*57:01 major histocompatibility complex class I allotype when utilising the drug abacavir as a part of their anti-retroviral regimen. The drug...
5.
Elliott T, van Hateren A
Biochemistry
. 2018 Feb;
57(9):1423-1425.
PMID: 29468875
No abstract available.
6.
van Hateren A, Anderson M, Bailey A, Werner J, Skipp P, Elliott T
J Biol Chem
. 2017 Oct;
292(49):20255-20269.
PMID: 29021251
Major histocompatibility complex class I molecules (MHC I) help protect jawed vertebrates by binding and presenting immunogenic peptides to cytotoxic T lymphocytes. Peptides are selected from a large diversity present...
7.
Neerincx A, Hermann C, Antrobus R, van Hateren A, Cao H, Trautwein N, et al.
Elife
. 2017 Apr;
6.
PMID: 28425917
Recently, we revealed that TAPBPR is a peptide exchange catalyst that is important for optimal peptide selection by MHC class I molecules. Here, we asked whether any other co-factors associate...
8.
van Hateren A, Bailey A, Elliott T
F1000Res
. 2017 Mar;
6:158.
PMID: 28299193
We have known since the late 1980s that the function of classical major histocompatibility complex (MHC) class I molecules is to bind peptides and display them at the cell surface...
9.
Tregaskes C, Harrison M, Sowa A, van Hateren A, Hunt L, Vainio O, et al.
Proc Natl Acad Sci U S A
. 2015 Dec;
113(3):692-7.
PMID: 26699458
The chicken major histocompatibility complex (MHC) has strong genetic associations with resistance and susceptibility to certain infectious pathogens. The cell surface expression level of MHC class I molecules varies as...
10.
Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition
Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, et al.
Mol Ther
. 2015 Nov;
24(2):375-384.
PMID: 26581160
The biggest roadblock in development of effective vaccines against human immunodeficiency virus type 1 (HIV-1) is the virus genetic diversity. For T-cell vaccine, this can be tackled by focusing the...